IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
16/26/16	1.200 kr	0.00%	5,74,367
15/26/15	1.200 kr	-3.38%	7,93,626
12/26/12	1.242 kr	-2.05%	65,122
11/26/11	1.268 kr	+2.42%	2,48,809
10/26/10	1.238 kr	-0.16%	68,834

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets 08:26:32 16/06/2026 pm IST			5-day change	1st Jan Change
1.200 ^SEK	0.00%		-3.23%	-39.09%

03:50pm	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
11:08am	Irlab highlights positive data for mesdopetam	FW

Market Cap	10Cr 1.09Cr 93.68L 86.22L 80.88L 1.52Cr 102.72Cr 1.53Cr 3.98Cr 50Cr 4.08Cr 3.99Cr 174.06Cr	P/E Ratio 2025 *	-	P/E Ratio 2026 *	-
Enterprise Value	10Cr 1.09Cr 93.68L 86.22L 80.88L 1.52Cr 102.72Cr 1.53Cr 3.98Cr 50Cr 4.08Cr 3.99Cr 174.06Cr	EV / Sales 2025	2.91x	EV / Sales 2026 *	1x
Free-Float	38.17%	Yield 2025 *	-	Yield 2026 *	-

03:50pm	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
11:08am	Irlab highlights positive data for mesdopetam	FW
08/06	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06/06	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
05/06	Irlab rights issue now 91 percent secured	FW
06/05	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
06/05	Irlab reports growth in revenue and operating profit	FW
06/05	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05/05	Verisure climbs on earnings, OMXS30 index gains 1.2 percent	FW
05/05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
05/05	Irlab launches SEK 68 million rights issue	FW
05/05	Irlab resolves on rights issue, obtains extended loan financing	RE
17/04	Christer Nordstedt Declines Re-Election as Board Member of IRLAB Therapeutics AB	CI

04/11	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
13/24/13	Irlab rises almost double-digit - Redeye raises motivated value	FW
13/24/13	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
12/24/12	Edison lowers motivated value for Irlab	FW
30/23/30	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

IRLAB Therapeutics AB Share Price

Stocks

IRLAB A

SE0012675361

Pharmaceuticals

Valuation: IRLAB Therapeutics AB

Chart: IRLAB Therapeutics AB

Latest news : IRLAB Therapeutics AB

Last Transcript: IRLAB Therapeutics AB

Analysts' recommendations: IRLAB Therapeutics AB

Press Releases: IRLAB Therapeutics AB

News in other languages: IRLAB Therapeutics AB

Quotes and Performance

Course Extremes

Managers and Directors: IRLAB Therapeutics AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

10:45am	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
10:30am	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ

1 week	-3.23%
Current month	-1.80%
1 month	-5.36%
3 months	-22.38%
6 months	-37.89%
Current year	-39.09%

1 week	1.18	1.27
1 month	1.18	1.32
Current year	1.17	2.14
1 year	1.17	7.27
3 years	1.17	20.2
5 years	1.17	81.8
10 years	1.17	110

Manager	Title	Age	Since
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	01/01/2016
Susanna Waters PRN	Corporate Officer/Principal	60	01/01/2013
Kristina Torfgård CEO	Chief Executive Officer	63	01/08/2024

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	01/01/2016
Gunnar Olof Olsson CHM	Chairman	73	07/05/2020
Carola Elisabet Lemne CHM	Chairman	68	20/02/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/25/29	Carola Elisabet Lemne	Buy	Chairman	36,000	45.1264%
27/25/27	Kristina Torfgård	Buy	Chief Executive Officer	75,589	94.7516%
18/25/18	Joakim Tedroff	Buy	Chief Technology Officer	3,57,327	447.9129%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB	0.00%	-3.23%	-82.73%	-84.25%	1.09Cr
ELI LILLY AND COMPANY	-0.16%	-1.42%	+39.72%	+152.03%	1,00700Cr
JOHNSON & JOHNSON	-1.12%	-1.78%	+49.97%	+41.75%	57TCr
ABBVIE INC.	-0.36%	-2.28%	+15.41%	+58.89%	39TCr
ROCHE HOLDING AG	-0.80%	+1.05%	+20.91%	+18.37%	33TCr
NOVARTIS AG	-0.67%	+0.83%	+23.86%	+31.51%	28TCr
ASTRAZENECA PLC	+0.47%	-2.57%	+22.78%	+12.67%	28TCr
NOVO NORDISK A/S	-1.86%	+4.01%	-43.73%	-49.21%	20TCr
AMGEN INC.	-0.78%	+0.74%	+17.45%	+51.15%	19TCr
GILEAD SCIENCES, INC.	+2.08%	+0.84%	+14.19%	+60.49%	15TCr
Average	-0.34%	-0.03%	+7.78%	+29.34%	33.86TCr
Weighted average by Cap.	-0.45%	-0.03%	+26.88%	+67.17%

	2025	2026 *
Net sales	5.63Cr 60.04L 51.75L 47.62L 44.68L 83.92L 57Cr 84.76L 2.2Cr 28Cr 2.25Cr 2.21Cr 96Cr	10Cr 1.09Cr 93.75L 86.28L 80.94L 1.52Cr 102.8Cr 1.54Cr 3.98Cr 50Cr 4.08Cr 4Cr 174.19Cr
Net income	-11Cr -1.17Cr -1.01Cr -92.79L -87.05L -1.64Cr -110.56Cr -1.65Cr -4.29Cr -54Cr -4.39Cr -4.3Cr -187.34Cr	-3.26Cr -34.76L -29.96L -27.58L -25.87L -48.59L -33Cr -49.08L -1.27Cr -16Cr -1.3Cr -1.28Cr -56Cr
Net Debt	-	-